acetic acid,(2S)-2,5-diaminopentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: acetic acid,(2S)-2,5-diaminopentanoic acid
• 英文别名: ethyl 2,5-diaminopentanoate;dihydrochloride
• 化学式: C7H18Cl2N2O2
• 分子量: 233.13
• InChiKey: FGDABGPSQJJTDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.46
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  78.3
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE
  申请人：Seikagaku Corporation

  公开号：EP3246037A1

  公开（公告）日：2017-11-22

  Provided is a chondroitin sulfate derivative having a structure cross-linked with a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

  本发明提供了一种硫酸软骨素衍生物，其结构与多价胺中的一个基团交联。还提供了一种含有该硫酸软骨素衍生物的组合物。还提供了一种用于治疗眼病的制剂和方法，该制剂和方法对角膜上皮疾病和/或干眼症具有治疗效果。
• DEGRADABLE SPIRAL COATED STENT WITH CONTROLLABLE GRADIENT, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Zhuhai Ruizhan Biomaterials Co., Ltd.

  公开号：EP3818995A1

  公开（公告）日：2021-05-12

  Disclosed are a spiral coated stent with controllable gradient degradation, a preparation method thereof and an application thereof. The spiral coated stent with controllable gradient degradation is composed of a degradable medical polyurethane and a degradable magnesium alloy material, wherein the degradable medical polyurethane contains a following chemical structure: PCL-PEG-PCL, wherein a molecular weight of the PEG is 200 to 1,000 and the molecular weight of the PCL is 200 to 10,000, and the degradable magnesium alloy material is of a spiral stent structure; and physical properties of the spiral coated stent with controllable gradient degradation need to satisfy the following technical parameters that: a breaking strength needs to be no less than 1 N, a pressure resistance needs to be no less than 2 N, and a degradation characteristic of the magnesium alloy after surface treatment shows gradient degradation with different time.

  本发明公开了一种可控梯度降解螺旋涂层支架、其制备方法及其应用。可控梯度降解螺旋涂层支架由可降解医用聚氨酯和可降解镁合金材料组成，其中可降解医用聚氨酯包含以下化学结构：PCL-PEG-PCL，其中PEG的分子量为200～1000，PCL的分子量为200～10000，可降解镁合金材料为螺旋支架结构；可控梯度降解螺旋涂层支架的物理性能需满足以下技术参数：断裂强度不小于1N，抗压强度不小于2N，镁合金表面处理后的降解特性随时间变化呈梯度降解。
• CROSS-LINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE
  申请人：Seikagaku Corporation

  公开号：EP3831394A1

  公开（公告）日：2021-06-09

  Provided is a chondroitin sulfate derivative having a structure cross-linked with a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye

  本发明提供了一种硫酸软骨素衍生物，其结构与多价胺中的一个基团交联。还提供了一种含有该硫酸软骨素衍生物的组合物。还提供了一种用于治疗眼疾的制剂和方法，该制剂和方法对角膜上皮疾病和/或干眼症具有治疗效果。
• Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease
  申请人：SEIKAGAKU CORPORATION

  公开号：US10420796B2

  公开（公告）日：2019-09-24

  Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

  本发明提供了一种硫酸软骨素衍生物，该衍生物通过多价胺中的一个基团具有交联结构。还提供了一种含有该硫酸软骨素衍生物的组合物。还提供了一种用于治疗眼疾的制剂和方法，该制剂和方法对角膜上皮疾病和/或干眼症具有治疗效果。
• [EN] DEGRADATION TIME CONTROLLABLE AND BREAKING ELONGATION ADJUSTABLE MEDICAL DEGRADABLE POLYURETHANE<br/>[FR] POLYURÉTHANE MÉDICAL DÉGRADABLE AJUSTABLE EN TERMES D'ALLONGEMENT À LA RUPTURE ET À TEMPS DE DÉGRADATION RÉGLABLE<br/>[ZH] 降解时间可控、断裂伸长率可调的医用可降解聚氨酯
  申请人：COMSCAFFOLDS NANJING MEDICAL DEVICE CO LTD

  公开号：WO2019076178A1

  公开（公告）日：2019-04-25

  本发明提供一种降解时间可控、断裂伸长率可调的医用可降解聚氨酯、制备方法及其应用，通过调整聚氨酯合成过程中各组分的比例以及选择不同的扩链剂，可以在很大范围内控制PU的性能，例如PU的降解时间、断裂伸长率、强度、润滑性以及亲疏水性等，可以根据再生医学以及植入体内的医疗器械的需要，选择不同性能的医用可降解聚氨酯。